Juvenile myelomonocytic leukemia surgery: Difference between revisions
(Created page with " {{Juvenile myelomonocytic leukemia}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{Hematological malignancy histology}} {{SIB}} Category:Hematology [[Category:T...") |
No edit summary |
||
Line 1: | Line 1: | ||
{{Juvenile myelomonocytic leukemia}} | {{Juvenile myelomonocytic leukemia}} | ||
{{CMG}} | {{CMG}} | ||
==Splenectomy== | |||
== | The theory behind splenectomy is that in JMML, the spleen acts as a trap for leukemic cells, which leads to their enlarged size. The fear is that since radiation and chemotherapy attack active leukemia cells rather than dormant ones, if the spleen is not removed it may harbor JMML cells that can later lead to relapse. The impact of splenectomy for post-transplant relapse, though, is unknown. The COG JMML Study includes splenectomy as a standard treatment for all clinically stable patients. The EWOG-MDS JMML Study allows each child’s physician to determine whether or not a spleenectomy should be done, and large spleens are commonly removed prior to bone marrow transplant. When a splenectomy is scheduled, JMML patients are advised to receive vaccines against Streptococcus pneumoneae and Haemophilus influenza at least 2 weeks prior to the procedure. Following splenectomy, penicillin may be administered daily in order to protect the patient against bacterial infections that the spleen would otherwise have protected against; this daily preventative regimen will usually continue until the patient is an adult. | ||
==References== | ==References== |
Revision as of 17:41, 23 January 2012
Juvenile myelomonocytic leukemia Microchapters |
Differentiating Juvenile myelomonocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Juvenile myelomonocytic leukemia surgery On the Web |
American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia surgery |
Risk calculators and risk factors for Juvenile myelomonocytic leukemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Splenectomy
The theory behind splenectomy is that in JMML, the spleen acts as a trap for leukemic cells, which leads to their enlarged size. The fear is that since radiation and chemotherapy attack active leukemia cells rather than dormant ones, if the spleen is not removed it may harbor JMML cells that can later lead to relapse. The impact of splenectomy for post-transplant relapse, though, is unknown. The COG JMML Study includes splenectomy as a standard treatment for all clinically stable patients. The EWOG-MDS JMML Study allows each child’s physician to determine whether or not a spleenectomy should be done, and large spleens are commonly removed prior to bone marrow transplant. When a splenectomy is scheduled, JMML patients are advised to receive vaccines against Streptococcus pneumoneae and Haemophilus influenza at least 2 weeks prior to the procedure. Following splenectomy, penicillin may be administered daily in order to protect the patient against bacterial infections that the spleen would otherwise have protected against; this daily preventative regimen will usually continue until the patient is an adult.